BRAF and thyroid gland papillary carcinoma: Xing et al. found that coexisting BRAF V600E and TERT mutations lead to worse clinicopathologic outcomes than isolated mutations with papillary thyroid cancer recurrence rates of 16.23% for BRAFV600E, 19.2% for TERT, and 68.6% for combined BRAFV600E and TERT [39].